Replies to post #236923 on Biotech Values

[Preciouslife1]

https://www.fool.com/investing/2021/02/02/will-pfizers-latest-bad-news-wipe-out-a-big-chunk/ . . . .

Good Morning Dew ... shalom blessings ...

[DewDiligence]

PFE’s $15B_with_high-20s-margin-2021_COVID-19-guidance_are_LOWBALL_ numbers—here’s_why:

https://twitter.com/DewDiligence/status/1356645214216216576

[DewDiligence]

USPTO extends Ibrance patent until 3/5/2027—(an additional four years):

https://finance.yahoo.com/news/pfizer-confirms-u-patent-term-114500130.html

Ibrance is currenlty PFE's second-largest-selling drug (after Prevnar-13); in 4Q20, Ibrance had annualized worldwide sales of $5.7B, approximately 2/3 in the US.

[DewDiligence]

PFE_to_develop_mRNA_vaccines_against_undisclosed_viruses—without_BNTX—(WSJ):

https://finance.yahoo.com/news/1-pfizer-develop-vaccines-own-102905685.html

https://www.wsj.com/articles/pfizer-goes-it-alone-to-expand-vaccine-business-beyond-covid-19-pandemic-11616491800

Pfizer will develop new shots using the technology, called mRNA, to target other viruses and pathogens beyond the coronavirus, Chief Executive Albert Bourla said in an interview. He said the company’s scientists and engineers gained a decade’s worth of experience in the past year working on the Covid-19 vaccine with Germany’s BioNTech and is ready to pursue mRNA on its own.

“[This] is a technology that has proven dramatic impact and dramatic potential,” Mr. Bourla said. “We are the best positioned company right now to take it to the next step because of our size and our expertise.”

PFE will continue its 50-50 partnership with BNTX on the COVID-19 vaccine, specifically.

[DewDiligence]

PFE—>$3.5B_COVID-19_vaccine_sales_in 1Q21—raises_2021_non-GAAP_EPS_guidance_to_$3.55-3.65 (from prior range of $3.10-3.20):

1Q21 PR:
https://s21.q4cdn.com/317678438/files/doc_financials/2021/q1/Q1-2021-PFE-Earnings-Release.pdf

CC slides:
https://s21.q4cdn.com/317678438/files/doc_financials/2021/q1/Q1-2021-Earnings-Charts-FINAL.pdf